Literature DB >> 16984679

Methodological approach for assessing the cost-effectiveness of treatments using longitudinal observational data: the SOHO study.

Frank Windmeijer1, Stathis Kontodimas, Martin Knapp, Jacqueline Brown, Josep Maria Haro.   

Abstract

OBJECTIVES: The objective of this study was to develop a method to allocate treatment effects when patients switch medication frequently in longitudinal observational studies and apply the approach to assess the cost-effectiveness of treatments in the Schizophrenia Outpatient Health Outcomes (SOHO) study.
METHODS: Data were collected on patients at entry to the SOHO study at 3, 6, and 12 months. The 12-month follow-up period was considered as three epochs: 0-3 months, 3-6 months, and 6-12 months. Patients who switched treatment at 3 months had their new treatment considered as a new baseline observation, as these two 3-month observations provide two sets of information on the cost-effectiveness of a drug in the first 3 months after initiation. Multivariate regression analysis was used to adjust for baseline covariates. The model allowed for flexible functional forms, and the cost data were modeled using an exponential mean function. Bootstrapping assessed the uncertainty of the estimated parameters and incremental cost-effectiveness analysis decision rule. RESULTS AND
CONCLUSIONS: We show the feasibility of the epoch analysis approach using data from the SOHO study comparing two antipsychotics. Estimates for the incremental cost and effectiveness per epoch over the full 12-month period are presented. Using the estimates of 200 bootstrap samples, we demonstrate how one drug is cost-effective compared with another.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16984679     DOI: 10.1017/S0266462306051385

Source DB:  PubMed          Journal:  Int J Technol Assess Health Care        ISSN: 0266-4623            Impact factor:   2.188


  5 in total

1.  Comparing the cost effectiveness of risperidone and olanzapine in the treatment of schizophrenia using the net-benefit regression approach.

Authors:  Annemieke De Ridder; Diana De Graeve
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

2.  Cost-utility analysis of treatment with olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the pan-European SOHO study.

Authors:  Martin Knapp; Frank Windmeijer; Jacqueline Brown; Stathis Kontodimas; Spyridon Tzivelekis; Josep Maria Haro; Mark Ratcliffe; Jihyung Hong; Diego Novick
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

3.  Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States.

Authors:  Nicolas M Furiak; Haya Ascher-Svanum; Robert W Klein; Lee J Smolen; Anthony H Lawson; Robert R Conley; Steven D Culler
Journal:  Cost Eff Resour Alloc       Date:  2009-04-07

4.  Calculating Total Health Service Utilisation and Costs from Routinely Collected Electronic Health Records Using the Example of Patients with Irritable Bowel Syndrome Before and After Their First Gastroenterology Appointment.

Authors:  Caroline Canavan; Joe West; Timothy Card
Journal:  Pharmacoeconomics       Date:  2016-02       Impact factor: 4.981

5.  Protocol for the IDEAL-2 longitudinal study: following the experiences of people with dementia and their primary carers to understand what contributes to living well with dementia and enhances active life.

Authors:  Barbora Silarova; Sharon M Nelis; Rosalie M Ashworth; Clive Ballard; Marta Bieńkiewicz; Catherine Henderson; Alexandra Hillman; John V Hindle; Julian C Hughes; Ruth A Lamont; Rachael Litherland; Ian R Jones; Roy W Jones; Martin Knapp; Piers Kotting; Anthony Martyr; Fiona E Matthews; Robin G Morris; Catherine Quinn; Jemma Regan; Jennifer M Rusted; Eleanor Ann van den Heuvel; Christina R Victor; Yu-Tzu Wu; Linda Clare
Journal:  BMC Public Health       Date:  2018-10-30       Impact factor: 3.295

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.